Parsortix cancer cell separation device diagnostic data

Researchers at Parsortix and the University of Surrey identified and confirmed that the Parsortix cancer cell separation device captured CTCs in 1 mL blood separations from patients with late-stage prostate cancer. The device has previously been shown to capture cultured prostate and breast cancer cells that were added to blood (see BioCentury, Dec. 19, 2011). In December, Parsortix partnered with the university to evaluate the capability of the cancer cell separation device to capture CTCs (see BioCentury, Dec. 12, 2011). ...